Pulmonary hypertension classification
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension classification On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension classification |
|
Risk calculators and risk factors for Pulmonary hypertension classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Richard Channick, M.D.; Assistant Editor(s)-in-Chief: Ralph Matar, Lisa Prior, Ann Slater, R.N.
Overview
Pulmonary hypertension has been previously divided into two categories: primary (currently known as idiopathic pulmonary arterial hypertension [IPAH]) and secondary. However; given the fact that some subcategories of secondary pulmonary hypertension share several similarities with primary pulmonary hypertension in terms of pathology, progression and response to therapy, the WHO (World Health Organization) has based its reclassification of pulmonary hypertension on the mechanism of the disease.
Classification
WHO Classification of Pulmonary Hypertension[1]
During the World Symposium on Pulmonary Hypertension (WSPH), five groups of disorders that cause pulmonary hypertension were identified: pulmonary arterial hypertension (Group 1); pulmonary hypertension due to left heart disease (Group 2); pulmonary hypertension due to chronic lung disease and/or hypoxia (Group 3); chronic thromboembolic pulmonary hypertension (Group 4); and pulmonary hypertension due to unclear multifactorial mechanisms (Group 5). This classification has been adopted by the Guidelines Committee of the European Society of Cardiology (ESC), European Respiratory Society (ERS), and International Society of Heart and Lung Transplantation (ISHLT), and is currently used by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the labelling of new drugs approved for pulmonary hypertension.
| “ |
|
” |
- Abbreviations: BMPR, bone morphogenic protein receptor type II; CAV1, caveolin-1; ENG, endoglin; HIV, human immunodeficiency virus.
Other Classification
The Venice 2003 Revised Classification System
In 2003, the 3rd World Symposium on Pulmonary Arterial Hypertension was convened in Venice to modify the classification based on the new understanding of disease mechanisms. The revised system developed by this group provides the current framework for understanding pulmonary hypertension.
The system includes several improvements over the former 1998 Evian Classification system. Risk factor descriptions were updated, and the classification of congenital systemic-to pulmonary shunts was revised. A new classification of genetic factors in PH was recommended, but not implemented because available data were judged to be inadequate.
The Venice 2003 Revised Classification system can be summarized as follows:[2]
- WHO Group I - Pulmonary arterial hypertension (PAH)
- WHO Group II - Pulmonary hypertension associated with left heart disease
- WHO Group III - Pulmonary hypertension associated with lung diseases and/or hypoxemia
- WHO Group IV - Pulmonary hypertension due to chronic thrombotic and/or embolic disease
- WHO Group V - Miscellaneous
Venice Clinical Classification of Pulmonary Hypertension (2003)
- 1. Pulmonary arterial hypertension (PAH)
- 1.1. Idiopathic (IPAH)
- 1.2. Familial (FPAH)
- 1.3. Associated with (APAH)
- 1.3.1. Collagen vascular disease
- 1.3.2. Congenital systemic-to-pulmonary shunts
- 1.3.3. Portal hypertension
- 1.3.4. HIV infection
- 1.3.5. Drugs and toxins
- 1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy)
- 1.4. Associated with significant venous or capillary involvement
- 1.4.1. Pulmonary veno-occlusive disease (PVOD)
- 1.4.2. Pulmonary capillary hemangiomatosis (PCH)
- 1.5. Persistent pulmonary hypertension of the newborn
- 2. Pulmonary hypertension with left heart disease
- 2.1. Left-sided atrial or ventricular heart disease
- 2.2. Left-sided valvular heart disease
- 3. Pulmonary hypertension associated with lung diseases and/or hypoxemia
- 3.1. Chronic obstructive pulmonary disease
- 3.2. Interstitial lung disease
- 3.3. Sleep-disordered breathing
- 3.4. Alveolar hypoventilation disorders
- 3.5. Chronic exposure to high altitude
- 3.6. Developmental abnormalities
- 4. Pulmonary hypertension owing to chronic thrombotic and/or embolic disease
- 4.1. Thromboembolic obstruction of proximal pulmonary arteries
- 4.2. Thromboembolic obstruction of distal pulmonary arteries
- 4.3. Nonthrombotic pulmonary embolism (tumor, parasites, foreign material)
- 5. Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis
References
- ↑ Simonneau, G.; Gatzoulis, MA.; Adatia, I.; Celermajer, D.; Denton, C.; Ghofrani, A.; Gomez Sanchez, MA.; Krishna Kumar, R.; Landzberg, M. (2013). "Updated clinical classification of pulmonary hypertension". J Am Coll Cardiol. 62 (25 Suppl): D34–41. doi:10.1016/j.jacc.2013.10.029. PMID 24355639. Unknown parameter
|month=ignored (help) - ↑ Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 2004 Jun 16;43(12 Suppl S):1S-90S. PMID 15194171.